1. Home
  2. CLDI vs ARTL Comparison

CLDI vs ARTL Comparison

Compare CLDI & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calidi Biotherapeutics Inc.

CLDI

Calidi Biotherapeutics Inc.

N/A

Current Price

$1.08

Market Cap

2.4M

Sector

Health Care

ML Signal

N/A

ARTL

Artelo Biosciences Inc.

N/A

Current Price

$4.00

Market Cap

2.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CLDI
ARTL
Founded
2014
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
2.5M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
CLDI
ARTL
Price
$1.08
$4.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
60.5K
★ 1.3M
Earning Date
11-12-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
★ $45,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.09
$0.52
52 Week High
$1.93
$19.91

Technical Indicators

Market Signals
Indicator
CLDI
ARTL
Relative Strength Index (RSI) N/A 49.69
Support Level N/A $3.20
Resistance Level N/A $6.81
Average True Range (ATR) 0.00 1.30
MACD 0.00 -0.25
Stochastic Oscillator 0.00 4.89

Price Performance

Historical Comparison
CLDI
ARTL

About CLDI Calidi Biotherapeutics Inc.

Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: